Year (case) | Age range/sex | Species | Bacteraemia—source | Antimicrobial susceptibility | Antimicrobial treatment | Significant medical history and risk factors |
---|---|---|---|---|---|---|
2004 | 80 + M | C. jejuni | Enteric—secondary | Fully sensitive | Nil | Age, nil other significant |
2005 (a) | 50–59 F | Campylobacter sp. | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | Acute myeloid leukaemia |
2005 (b) | 60–69 F | Campylobacter sp. | Enteric—secondary | Fully sensitive | Nil | Nil significant |
2005 (c) | 40–49 F | C. jejuni | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | IV drug use, PUD on omeprazole |
2006 (a) | 40–49 M | C. jejuni | Enteric— secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | Untreated Stage III HIV |
2008 (a) | 20–29 M | Campylobacter sp. | Enteric—secondary | Fully sensitive | IV azithromycin 500 mg qd | Nil significant |
2008 (b) | 60–69 M | C. coli | Primary bacteraemia | Ciprofloxacin- Resistant Erythromycin- Resistant | Nil | Lymphocytic lymphoma |
2009 | 30–39 F | C. jejuni | Enteric—secondary | Fully sensitive | PO ciprofloxacin 250 mg bd | History of renal transplant secondary to IgA nephropathy |
2010 (a) | 60–69 M | Campylobacter sp. | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | Bowel carcinoma, current chemotherapy |
2010 (b) | 30–39 M | C. coli | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | Alcoholic liver disease with portal hypotension and bleeding varices |
2010 (c) | 70–79 F | C. jejuni | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | T2DM |
2010 (d) | 10–19 F | C. jejuni | Enteric—secondary | Fully sensitive | PO azithromycin 500 mg qd (upon discharge) | Nil significant. |
2010 (e) | 70–79 F | C. coli | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | T2DM |
2010 (f) | 40–49 M | C. jejuni | Enteric—secondary | Fully sensitive | PO Norfloxacin 400 mg bd | Irritable bowel syndrome |
2011 (a) | 60–69 M | C. lari | Enteric—secondary | Ciprofloxacin— Resistant | PO Doxycycline 100 mg bd | Alcoholic liver disease with portal hypotension, recent intracerebral bleed |
2011 (b) | 80 + M | C. jejuni | Enteric—secondary | Fully sensitive | Nil prescribed | Age, nil other significant |
2011 (c) | 70–79 M | C. coli | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | Asplenic |
2012 (a) | 40–49 M | C. jejuni | Enteric—secondary | Fully sensitive | IV ciprofloxacin 500 mg bd | Multiple sclerosis, current chemotherapy pre-stem cell transplantation, IDDM |
2012 (b) | 30–39 F | C. jejuni | Enteric—secondary | Fully sensitive | Nil | Pregnant 33/40K, IDDM |
2012 (c) | 70–79 M | C. jejuni | Enteric—secondary | Ciprofloxacin— Resistant Nalidixic acid— Resistant | Nil | Diabetic neuropathy, chronic renal failure |
2012 (d) | 60–69 F | C. coli | Enteric—secondary | Ciprofloxacin— Resistant Nalidixic acid— Resistant | Nil | Nil significant |
2013 (a) | 20–29 M | C. jejuni | Enteric—secondary | Fully sensitive | Nil | Nil significant |
2013 (b) | 20–29 M | C. jejuni | Primary bacteraemia | Fully sensitive | PO Ciprofloxacin 750 mg bd (upon discharge) | B cell leukaemia, AVN (on steroids), SIADH |
2013 (c) | 50–59 M | C. jejuni | Enteric—secondary | Fully sensitive | PO ciprofloxacin 500 mg bd | Liver failure with cirrhosis, portal hypotension secondary to Hepatitis C, T2DM, hypothyroidism. Awaiting transplant. |
2013 (d) | 70–79 M | C. jejuni | Enteric—secondary | Fully sensitive | Nil | Age, nil other significant |